Weixin Kang: Subsidiary’s injectable Itraconazole drug obtains registration certificate

Weixin Kang announces that recently, its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for Intravenous Itraconazole issued and approved by the National Medical Products Administration.
This drug is used to treat the following infections in adult patients: invasive aspergillosis, invasive mucormycosis.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin